Research

 

Clinical Research Trials

Retinal diseases are a leading cause of vision loss and blindness, affecting millions of people worldwide. Clinical trials are vital to the development of new treatments and therapies for these conditions, and there are many ongoing trials testing promising new approaches.

Star Retina is proud to take part in clinical research trials for many common retinal conditions. Below are trials for which we are currently enrolling new patients and those that have been completed.

Open Trials

Sponsor: OcuTerra-OTT 166-201 DREAM OTT166-201 A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR)
Sponsor: ORA Cognition Therapeutics (PILL STUDY) A Randomized, Double-Masked, Placebo-controlled, Parallel group, Phrase 2 Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants with Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

ETA:<DECEMBER

Sponsor: RegenexBio ATMOSPHERE a randomized partially masked controlled clinical study to evaluate the efficacy and safety of RGX-314 Gene Therapy in participants with nAMD. Lucentis

Sponsor: RegenxBio ASCENT a randomized partially masked controlled clinical study to evaluate the efficacy and safety of RGX-314 Gene Therapy in participants with nAMD. Eyela

Sponsor: Opthea OPT-302-1005 COAST Eyela OPT-302-1005-COAST A Phase 3, Multicentre, Double-masked, Randomized Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)

Closed Trials

Sponsor: KODIAK GLEAM A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME)

ETA: CLOSED

Sponsor: KODIAK GLOW A Prospective, Randomized, Double-masked, Active Comparatorcontrolled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME)

ETA: CLOSED

Sponsor: ORA ANX007-GA-0 A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) Geographic Atrophy (GA)

ETA: CLOSED

Sponsor: KODIAK Daylight A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD) (DAYLIGHT)

ETA: CLOSED

For referring doctors or patients who wish to learn more about our research protocols or activities, please continue reading below or contact our office at 817-378-4777

WARNING: Internet Explorer does not support modern web standards. This site may not function correctly on this browser and is best viewed on Chrome, Firefox or Edge browsers. Learn More.